Form 4: Pharvaris Director Sells Shares Under 10b5-1 Plan

Pharvaris N.V. Director Johannes Schikan sold 7,100 shares of common stock under a pre-arranged 10b5-1 trading plan.

Summary

• Johannes Schikan, a Director at Pharvaris N.V., reported a transaction involving the sale of common stock.
• The sale of 7,000 shares occurred on April 22, 2026, at a price of $30.0541 per share, resulting in 388,167 shares beneficially owned.
• An additional 100 shares were sold on April 23, 2026, at $30.03 per share, leaving 388,067 shares beneficially owned.
• These transactions were executed as part of a Rule 10b5-1 trading plan, indicating a pre-scheduled sale.
• The shares were sold in multiple transactions at prices ranging from $30 to $30.13.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it reports routine insider stock transactions executed under a pre-established plan, without indicating new company performance or strategic shifts.

Future Outlook

No specific future outlook or guidance is provided in this filing, as it pertains to a director's stock transaction.

Industry Context

StockSavvy.ai notes that Form 4 filings, like this one from Pharvaris N.V., are standard disclosures for insider stock transactions. The use of a 10b5-1 plan suggests a pre-determined strategy for stock sales, often employed by executives to avoid perceptions of insider trading.

Stakeholder Impact

• Shareholders: The sale of shares by a director may be interpreted by some shareholders as a signal, though the use of a 10b5-1 plan mitigates concerns about insider trading based on non-public information.

Key Dates

Keywords

Pharvaris N.V., PHVS, Form 4, Insider Trading, Stock Sale, 10b5-1 Plan, Director Transaction, Beneficial Ownership